SNDL
SNDL, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.43
+5.56%Year over year
Reported trailing growth
- Revenue
- -3.3%
- EBITDA
- +224.8%
- EBIT
- +89.4%
- EPS
- +29.9%
- Free cash flow
- -28.3%
- Operating cash flow
- -27.2%
Forward estimates
Based on analyst estimates
- Revenue
- -6.8%
- EBITDA
- -1.3%
- EPS
- +85.8%
Three-year CAGR
- Revenue
- +9.9%
- EBITDA
- +216.5%
- EBIT
- +95.7%
- Net income
- +83.4%
- EPS
- +84.1%
- Free cash flow
- +32.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026